Continuous renal replacement therapy (CRRT) is a common technique in critically ill patients. However, there is no uniformity in the pharmacokinetics of ciprofloxacin (CPFX) used during CRRT. The aims of the present study were to estimate the pharmacokinetics of CPFX and to determine the appropriate administration of CPFX for critically ill patients undergoing CRRT. The pharmacokinetics of ciprofloxacin total clearance (CL tot ) was calculated based on the creatinine clearance (CL cre ), dialysate flow (Q D ), and ultrafiltrate flow (Q F ) as follows: CL tot(L/h) ‫؍‬ (4.83 CL cre(L/h) ؉ 6.41) ؉ 0.92 (Q D ؉ Q F(L/h) ) based on in vitro study using CRRT circuit model. We administered CPFX to critically ill patients based on the CL tot , which was 50 ؋ CL tot(L/h) (mg/day). We confirmed that the CPFX concentrations reached higher than optimal concentrations, and infection was successfully controlled in these patients. ASAIO Journal 2009; 55:243-245.
Continuous renal replacement therapy (CRRT) is a common technique used to treat renal failure in critically ill patients. However, there is no uniformity in the pharmacokinetics of the drugs used during CRRT. The pharmacokinetics of Ciprofloxacin (CPFX), used in treatment of severe infections, 1 are affected by both the renal function and CRRT. 2, 3 The aim of the present study was to establish a wide use dosage-regimen method to calculate the optimal dosage for CPFX in critically ill patients during CRRT. For this purpose, we examined as follows: 1) estimated the CPFX total clearance (CL tot ) during CRRT based on dialysate flows (Q D ), the ultrafiltrate flows (Q F ), and renal function of the patient, 2) determined the appropriate dose of CPFX based on the CL tot , and 3) confirmed CPFX pharmacokinetics in critically ill patients receiving CRRT when the dose determined based on CL tot was administered.
Materials and Methods
To Estimate CL tot During CRRT A CRRT system (ACH-10, Asahi Medical Co., Tokyo, Japan) was used. A CRRT circuit was set up using a cellulose triacetate hollow fiber 1.1 m 2 hemofilter (UT-110, Nipro, Japan).
The machine was primed with a 5% bovine serum albumin (BSA) solution. Twenty milligrams of CPFX were added to 200 ml of the 5% BSA solution in the reservoir. The CRRT conditions were as follows: the BSA solution flow was fixed at 9 L/h; Q D was defined from 0, 1, and 2 L/h; Q F was defined from 0, 1, and 2 L/h independently of Q D . Normal saline was used as a dialysate, and it also served as a replacement fluid which was infused postdilusionally with an equal amount of Q F . We took samples from the prehemofilter and the filtrates at 15, 30, 45, and 60 minutes after the start of CRRT. Each variation was performed twice and the clearance by CRRT (CL CRRT ) was calculated two times based on Q D , Q F , and CPFX concentrations in the filtrate and prehemofilter. The concentrations of CPFX were determined using the high-performance liquid chromatography method. 4 The pharmacokinetics of ciprofloxacin clearance in patients (CL vivo ) was based on the creatinine clearance (CL cre ) in a previous study. 2 The CPFX CL tot in a patient during CRRT was calculated as follows:
To Determine the Appropriate Dose of CPFX Clinical success has been obtained when the target of the area under the plasma is concentration-time curve (AUC) [(mg/L) ⅐ h] / minimum inhibitory concentration (MIC) (mg/L) Ն100 (h) . 5 In a majority of bacteria, the MIC required to inhibit the growth of 90% of the strains for CPFX was Ͻ0.5 mg/L. 1 Therefore, we determined the target of AUC to be Ն50 [(mg/L) ⅐ h]. We determined the optimal dose to be 50 ϫ CL tot(L/h) (mg/d) in order to maintain the target of AUC based on the CL tot .
To Confirm CPFX Pharmacokinetics in Critically Ill Patients Receiving CRRT
Three patients with acute renal failure were studied. Table 1 shows the patients' clinical backgrounds. In all patients, CL tot was calculated and the optimal CPFX doses determined based on the CL tot were administered intravenously. A CRRT system (JUN600, UBE, Japan) was used. The same hemofilter as that used in the in vitro study was used. The dialysate and replacement fluid were Sublood-A (Fuso, Japan). The CRRT conditions were as follows: The blood circuit pumped 6 L/h; Q F was defined as 1.0 L/h in all patients; Q D was infused in a countercurrent at rates of 1.0 L/h. The replacement fluid was infused after dilution as clinically indicated. The sampling points were prehemofilter and the filtrates. The samples were taken before the start of the next CPFX administration, at 1, 1.5, 2, 6, and 12 hours after the start of the drug administration. The CPFX concentrations were determined by the high-performance liquid chromatography method. 4 A pharmacokinetic analysis was performed using the nonlinear least-squares regression program. 6 The parameters were calculated by a two-compartment open model with a constant rate of infusion. The AUC was calculated using the trapezoidal rule.
Results
The clearance by CRRT obtained by interpolation into a simple linear regression of CL CRRT against Q D ϩ Q F closely correlates with the experimental data (Figure 1) . The pharmacokinetics of ciprofloxacin CL tot was calculated as follows:
The pharmacokinetics of ciprofloxacin total clearance in the patients were presented in Table 1 . The CPFX doses in all patients were set at 600 mg/d. The pharmacokinetics of ciprofloxacin at a dose of 300 mg was administered during a 60 minutes period every 12 hours. The CPFX concentrations curve is presented in Figure 2 . Table 2 shows the pharmacokinetic parameters. The mean of actual AUC reached a level higher than the target AUC. The infections of the patients were successfully controlled.
Discussion
Several reports have described the achievement of AUC/ MIC Ն100 to demonstrate a good clinical outcome. 5 However, a high dose of CPFX is needed to achieve the target of AUC/MIC. Lipman et al. 7 concluded that an intravenous dosage of 400 mg 3 times daily was safe and effective in patients with severe sepsis. In a clinical study, we confirmed that the actual AUC [54.9 32 Ϯ 12.8 (mg/L) ⅐ h] was higher than the targeted AUC [50 (mg/L) ⅐ h], when the CPFX amounts, based on the CL tot , were intravenously administered. This result showed that the CL tot formula as determined, based on the findings of an in vitro study, is therefore appropriate.
In CRRT, high-flux membranes with large pores and no drug-adsorption are recommended. The hemofilter used in this study was a cellulose tri-acetate membrane with the recommended characteristics. The pore size of the hemofilter may not influence the CL CRRT because of the sufficiently low molecular weight of CPFX. 1, 4 The surface area of the hemofilter may affect the clearance of small solute when Q D is large amount. 8 Therefore, the results of the present study are not considered to be adaptable to the follow situations: 1) the hemofilter has drug-adsorption ability; 2) when Q D is a large amount, then the hemofilter has a much different surface area from that used in the present study.
In conclusion, we estimated CL tot during CRRT based on Q D , Q F , and renal function of the patient. We established a wide use dosage-regimen calculation of CPFX, which was 50 ϫ [(4.83 CL cre ϩ 6.41) ϩ 0.92 (Q D ϩ Q F )] (mg/d) in critically ill patients during CRRT. Furthermore, we con- firmed that the wide use dosage-regimen method is also appropriate in a clinical setting.
